Log in

NASDAQ:CERS - Cerus Stock Price, Forecast & News

$5.16
-0.25 (-4.62 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$5.06
Now: $5.16
$5.40
50-Day Range
$4.01
MA: $4.55
$5.41
52-Week Range
$3.70
Now: $5.16
$6.88
Volume1.96 million shs
Average Volume2.12 million shs
Market Capitalization$819.82 million
P/E RatioN/A
Dividend YieldN/A
Beta1.57
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:CERS
CUSIP15708510
Phone925-288-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$74.65 million
Book Value$0.62 per share

Profitability

Net Income$-57,560,000.00

Miscellaneous

Employees240
Market Cap$819.82 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.


Cerus (NASDAQ:CERS) Frequently Asked Questions

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) released its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.01. The biotechnology company earned $18 million during the quarter, compared to the consensus estimate of $17.69 million. Cerus had a negative net margin of 95.44% and a negative return on equity of 109.08%. The business's revenue for the quarter was up 16.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.11) earnings per share. View Cerus' Earnings History.

When is Cerus' next earnings date?

Cerus is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Cerus.

What guidance has Cerus issued on next quarter's earnings?

Cerus issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 20th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $89-93 million, compared to the consensus revenue estimate of $110.77 million.

What price target have analysts set for CERS?

3 brokers have issued 12 month price targets for Cerus' shares. Their forecasts range from $7.00 to $8.00. On average, they expect Cerus' stock price to reach $7.33 in the next twelve months. This suggests a possible upside of 42.1% from the stock's current price. View Analyst Price Targets for Cerus.

What is the consensus analysts' recommendation for Cerus?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cerus.

Has Cerus been receiving favorable news coverage?

Media headlines about CERS stock have trended extremely negative recently, InfoTrie reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cerus earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Cerus.

Who are some of Cerus' key competitors?

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Opko Health (OPK), Celldex Therapeutics (CLDX), Omeros (OMER), Grayscale Bitcoin Trust (Btc) (GBTC) and Aduro BioTech (ADRO).

Who are Cerus' key executives?

Cerus' management team includes the folowing people:
  • Mr. William M. Greenman, Pres, CEO & Director (Age 52)
  • Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 75)
  • Mr. Kevin D. Green, VP of Fin. & CFO (Age 47)
  • Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 48)
  • Dr. Richard J. Benjamin, Chief Medical Officer (Age 59)

Who are Cerus' major shareholders?

Cerus' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (6.96%), Nikko Asset Management Americas Inc. (6.15%), ARK Investment Management LLC (6.71%), State Street Corp (2.52%), Peregrine Capital Management LLC (1.70%) and Senvest Management LLC (1.26%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman. View Institutional Ownership Trends for Cerus.

Which institutional investors are selling Cerus stock?

CERS stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, King Luther Capital Management Corp, Bank of America Corp DE, Bamco Inc. NY, Principal Financial Group Inc., Senvest Management LLC, New York State Common Retirement Fund and UBS Group AG. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Insider Buying and Selling for Cerus.

Which institutional investors are buying Cerus stock?

CERS stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., ARK Investment Management LLC, State Street Corp, Peregrine Capital Management LLC, Jacobs Levy Equity Management Inc. and Millrace Asset Group Inc.. Company insiders that have bought Cerus stock in the last two years include Laurence M Corash, Timothy L Moore and William Mariner Greenman. View Insider Buying and Selling for Cerus.

How do I buy shares of Cerus?

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $5.16.

How big of a company is Cerus?

Cerus has a market capitalization of $819.82 million and generates $74.65 million in revenue each year. The biotechnology company earns $-57,560,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 240 workers across the globe.View Additional Information About Cerus.

What is Cerus' official website?

The official website for Cerus is http://www.cerus.com/.

How can I contact Cerus?

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]


MarketBeat Community Rating for Cerus (NASDAQ CERS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  526 (Vote Outperform)
Underperform Votes:  367 (Vote Underperform)
Total Votes:  893
MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote "Outperform" if you believe CERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel